Physician profile
Danielle L Gilbert
NPI 1629692587
$583.71
in general payments reported to CMS, 2019-2025
11 companies · $183 in 2025
The $183 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $32.95 · 2021: $153 · 2022: $177 · 2023: $37.27 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $220.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $183.19 | 2025 | Rukobia |
| Incyte Corporation | $116.32 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.16 | 2021-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $67.69 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.60 | 2022-2023 | |
| Lilly USA, LLC | $21.89 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $21.55 | 2021 | |
| Sanofi-Aventis U.S. LLC | $19.23 | 2020 | |
| Mylan Specialty L.P. | $15.60 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.76 | 2021 | |
| Astellas Pharma US INC | $13.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Gilbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.